JohnWDayMDPhD

Neurology • Stanford, CA

Neuromuscular Medicine, Neurophysiology

Professor, Neurology & Neurological Sciences and Pediatrics, Stanford University School of Medicine

Join to view full profile

Dr. Day is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Day's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-723-7299

Education & Training

University of California (San Francisco)Residency, Neurology, 1983 - 1986
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Internship, Internal Medicine, 1982 - 1983
University of Minnesota Medical SchoolClass of 1977

Certifications & Licensure

CA State Medical License 2011 - 2025
MN State Medical License 1992 - 2022
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others Start of enrollment: 2010 Apr 01
Recruiting
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Start of enrollment: 2014 Aug 19
Terminated
Phase 3
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Start of enrollment: 2015 Jun 30
Completed
Phase 2
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Start of enrollment: 2017 Jul 06
Completed
Phase 3
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 Start of enrollment: 2017 Oct 24
Completed
Phase 3
Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 Start of enrollment: 2018 Apr 02
Completed
Phase 3
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy Start of enrollment: 2021 Mar 03
Completed
Phase 2, Phase 3
Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Start of enrollment: 2013 Dec 01
Unknown status
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded.
Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, Matthew Civitello, Annemarie Rohwer
European Journal of Neurology. 2024-12-01
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module.
Giorgia Coratti, Matthew Civitello, Annemarie Rohwer, Emilio Albamonte, Jacqueline Montes
Neuromuscular Disorders. 2024-11-01
1 citations
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An internationa...
Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, Mariacristina Scoto, Jacqueline Montes
European Journal of Neurology. 2024-08-01

Journal Articles

Telomere Shortening Is a Hallmark of Genetic Cardiomyopathies
Christine E Seidman, John T Hinson, Gerhard Weber, Euan Ashley, John W Day, Joseph C Wu, Proceedings of the National Academy of Sciences

Lectures

Pump It Up! Acute Neuromuscular Disorders You Should Not Miss
10/12/2014

Press Mentions

MDA’s Medical Advisory Team to Help Guide Research and Patient CareApril 28th, 2020
Diseased Heart Muscle Cells Have Abnormally Shortened TelomeresAugust 27th, 2018
Cytokinetics Announces Presentation of Data from Phase 2 Clinical Study of Reldesemtiv in Patients with Spinal Muscular Atrophy at the 2018 Annual Cure SMA ConferenceJune 9th, 2018
Join now to see all